Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8129 USD | +9.01% | +9.08% | -60.15% |
Apr. 15 | Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform | CI |
Apr. 02 | Top Midday Decliners | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.15% | 86.49M | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+56.21% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
+7.79% | 8.31B |
- Stock Market
- Equities
- GRTS Stock
- News Gritstone bio, Inc.
- Gritstone Oncology : BTIG Research Adjusts Gritstone Oncology PT to $35 From $17, Maintains Buy Rating